Free Trial

NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma logo
$19.51 -0.63 (-3.15%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NAMS vs. KRYS, PTGX, RYTM, KNSA, and ALKS

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Krystal Biotech (KRYS), Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals International (KNSA), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Krystal Biotech?

NewAmsterdam Pharma (NASDAQ:NAMS) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

NewAmsterdam Pharma has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.89 beat NewAmsterdam Pharma's score of 0.26 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has a net margin of 47.91% compared to NewAmsterdam Pharma's net margin of -789.95%. Krystal Biotech's return on equity of 17.02% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Krystal Biotech 47.91%17.02%15.48%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NewAmsterdam Pharma presently has a consensus price target of $49.82, indicating a potential upside of 147.36%. Krystal Biotech has a consensus price target of $375.00, indicating a potential upside of 22.86%. Given NewAmsterdam Pharma's higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93

Krystal Biotech has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M107.35-$203.82M-$1.69N/A
Krystal Biotech$389.13M23.24$204.83M$7.3741.42

Summary

Krystal Biotech beats NewAmsterdam Pharma on 13 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Protagonist Therapeutics presently has a consensus target price of $166.67, suggesting a potential upside of 27.28%. NewAmsterdam Pharma has a consensus target price of $49.82, suggesting a potential upside of 147.36%. Given NewAmsterdam Pharma's higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Protagonist Therapeutics has a net margin of 62.04% compared to NewAmsterdam Pharma's net margin of -789.95%. Protagonist Therapeutics' return on equity of 42.83% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics62.04% 42.83% 40.29%
NewAmsterdam Pharma -789.95%-31.39%-28.32%

Protagonist Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74
NewAmsterdam Pharma$22.50M107.35-$203.82M-$1.69N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Protagonist Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

In the previous week, Protagonist Therapeutics had 7 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 19 mentions for Protagonist Therapeutics and 12 mentions for NewAmsterdam Pharma. Protagonist Therapeutics' average media sentiment score of 0.97 beat NewAmsterdam Pharma's score of 0.26 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Protagonist Therapeutics beats NewAmsterdam Pharma on 14 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Rhythm Pharmaceuticals?

NewAmsterdam Pharma (NASDAQ:NAMS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

NewAmsterdam Pharma currently has a consensus price target of $49.82, suggesting a potential upside of 147.36%. Rhythm Pharmaceuticals has a consensus price target of $142.00, suggesting a potential upside of 23.46%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77

NewAmsterdam Pharma has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M107.35-$203.82M-$1.69N/A
Rhythm Pharmaceuticals$189.76M42.02-$196.54M-$2.90N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 8 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.66 beat NewAmsterdam Pharma's score of 0.26 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rhythm Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rhythm Pharmaceuticals has a net margin of -69.03% compared to NewAmsterdam Pharma's net margin of -789.95%. NewAmsterdam Pharma's return on equity of -31.39% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Rhythm Pharmaceuticals -69.03%-171.16%-43.00%

Summary

NewAmsterdam Pharma beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Kiniksa Pharmaceuticals International has a net margin of 11.58% compared to NewAmsterdam Pharma's net margin of -789.95%. Kiniksa Pharmaceuticals International's return on equity of 17.27% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International11.58% 17.27% 12.64%
NewAmsterdam Pharma -789.95%-31.39%-28.32%

Kiniksa Pharmaceuticals International has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals International$945.96M8.00$59.01M$1.3074.10
NewAmsterdam Pharma$22.50M107.35-$203.82M-$1.69N/A

Kiniksa Pharmaceuticals International presently has a consensus price target of $100.57, indicating a potential upside of 4.40%. NewAmsterdam Pharma has a consensus price target of $49.82, indicating a potential upside of 147.36%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 10 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.90 beat NewAmsterdam Pharma's score of 0.26 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals International
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kiniksa Pharmaceuticals International beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Alkermes?

NewAmsterdam Pharma (NASDAQ:NAMS) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Alkermes has higher revenue and earnings than NewAmsterdam Pharma. Alkermes is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M107.35-$203.82M-$1.69N/A
Alkermes$1.48B5.35$241.66M-$0.02N/A

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NewAmsterdam Pharma currently has a consensus price target of $49.82, indicating a potential upside of 147.36%. Alkermes has a consensus price target of $55.73, indicating a potential upside of 18.51%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

NewAmsterdam Pharma has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

In the previous week, Alkermes had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for Alkermes and 12 mentions for NewAmsterdam Pharma. Alkermes' average media sentiment score of 0.99 beat NewAmsterdam Pharma's score of 0.26 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a net margin of -0.02% compared to NewAmsterdam Pharma's net margin of -789.95%. Alkermes' return on equity of 0.40% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Alkermes -0.02%0.40%0.19%

Summary

Alkermes beats NewAmsterdam Pharma on 11 of the 16 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMS vs. The Competition

MetricNewAmsterdam PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.35B$4.08B$7.84B$11.78B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-11.6124.3334.3430.14
Price / Sales90.1915.078.085.36
Price / CashN/A21.8921.0222.32
Price / Book3.274.384.783.86
Net Income-$203.82M-$24.19M$3.52B$391.27M
7 Day Performance2.66%-6.70%-4.96%-4.25%
1 Month Performance-1.63%-4.36%-3.18%-5.57%
1 Year Performance-49.14%-4.10%-0.28%-7.49%

NewAmsterdam Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMS
NewAmsterdam Pharma
3.433 of 5 stars
$19.51
-3.1%
$49.82
+155.4%
-47.5%$2.35B$25.94MN/A100
KRYS
Krystal Biotech
3.7465 of 5 stars
$306.50
+1.1%
$375.00
+22.3%
+48.1%$8.98B$389.13M41.12295
PTGX
Protagonist Therapeutics
3.5254 of 5 stars
$136.26
+0.3%
$166.67
+22.3%
+54.8%$8.87B$46.02M28.79141
RYTM
Rhythm Pharmaceuticals
2.6233 of 5 stars
$113.95
+0.0%
$142.00
+24.6%
+15.7%$7.90B$189.76MN/A414
KNSA
Kiniksa Pharmaceuticals International
3.3749 of 5 stars
$95.02
-3.8%
$100.57
+5.8%
+138.9%$7.76B$677.56M73.09366

Related Companies and Tools


This page (NASDAQ:NAMS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners